Panacea Biotec Pharma Limited, a active public limited company, was established on 22 March 2019 in New Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24299DL2019PLC347566. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹60.00 Cr and a paid-up capital of ₹1.00 M.
Employing 749 professional, Its leadership includes Ankesh Jain (Whole-Time Director), Rajesh Jain (Director), Manjula Upadhyay (Director). Past directors included Shantanu Yeshwant Nalavadi, Ankesh Jain, Krishna Murari Lal. It holds no open charges and ₹1,618.44 Cr settled loans. Its latest AGM occurred on 26 September 2024, with the balance sheet filed on 31 March 2024. It is based at B-1 Extension/A-27, Mohan Co-Operative Industrial Estate, Mathura Road, New Delhi, Delhi, 110044.
U24299DL2019PLC347566
347566
22 March 2019
₹60.00 Cr
₹1.00 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Panacea Biotec Pharma Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ankesh Jain | Whole-Time Director | 22 Mar 2019 | Current |
| Rajesh Jain | Director | 12 Nov 2024 | Current |
| Manjula Upadhyay | Director | 23 Jul 2021 | Current |
| Rajesh Jain | Managing Director | 22 Mar 2019 | Current |
| Sanjay Trehan | Whole-Time Director | 13 Feb 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Nominee Director | 10 Dec 2020 | Past |
| Pramod Abcsdd | Director | 31 May 2024 | Past |
| Pramod Abcsdd | Additional Director | 11 Dec 2020 | Past |
| Pramod Abcsdd | Additional Director | 05 Dec 2024 | Past |
| Pramod Abcsdd | Additional Director | 30 Jul 2021 | Past |
| Pramod Abcsdd | Additional Director | 01 Apr 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Panacea Biotec Pharma Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 46.22% decrease. The company also saw a substantial fall in profitability, with a 95.54% decrease in profit. The company's net worth Soared by an impressive increase of 12.6%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Panacea Biotec Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹16,184,448,363.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Feb 2020 | Others | ₹754.44 Cr | Satisfied |
| 06 Apr 2019 | Others | ₹864.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Panacea Biotec Pharma has a workforce of 749 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Panacea Biotec Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Panacea Biotec Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Sanjay Trehan was appointed as a Whole-time director was appointed as a Whole-time director on 13 Feb 2025 & has been associated with this company since 9 months 11 days . was recorded as a recent event.
Rajesh Jain was appointed as a Director was appointed as a Director on 12 Nov 2024 & has been associated with this company since 1 year 12 days . was recorded as a recent event.
Panacea Biotec Pharma Limited last Annual general meeting of members was held on 26 Sep 2024 as per latest MCA records. was recorded as a recent event.
Progress on Panacea Biotec Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was documented.
A charge registered on 01 Feb 2020 via Charge ID 100332250 with Others was fully satisfied on 03 Mar 2022. was recorded as a recent event.
The activity A charge with Others of Rs. 754.44 Cr registered on 01 Feb 2020 with Charge ID 100332250 was modified on 16 Nov 2021. was completed.
Six in one has the potential of over 250 million doses in next 3-4 years with a market size of over $1.25 Billion annually..
India Business News: New Delhi, Dec 27 () Drug firm Panacea Biotec has filed a review petition against the grant of a patent with regard to a pneumonia vaccine to the US-b.
"The company's first-to-file abbreviated new drug application (ANDA) of Prasugrel 5 mg and 10 mg tablets has been approved by the US Food and Drug Administration (USFDA)," Panacea Biotec said in a BSE filing..
Mumbai: Panacea Biotec said that it has received the Certificate of GMP compliance from State Service of Ukraine on Medicines and Drugs Control with Manufacturing Authorization for 22 medicinal... .
Panacea Biotec signs an agreement with Canada's Apotex to launch Prasugrel 5mg and 10mg tablets, used for the treatment of certain coronary diseases, in the US.
The CIN of Panacea Biotec Pharma Limited is U24299DL2019PLC347566.
Panacea Biotec Pharma Limited is headquartered at B-1 Extension/A-27, Mohan Co-Operative Industrial Estate, Mathura Road, New Delhi, Delhi, 110044.
Panacea Biotec Pharma Limited was incorporated on 22 March 2019.
The current directors of Panacea Biotec Pharma Limited are
The primary industry of Panacea Biotec Pharma Limited is Manufacturing.
Panacea Biotec Pharma Limited is unlisted.
The authorized capital of Panacea Biotec Pharma Limited is ₹60.00 Cr, and the paid-up capital is ₹1.00 M.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX